Advanced search
Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 42, 2023 - Issue 4
Submit an article Journal homepage
231
Views
3
CrossRef citations to date
0
Altmetric
Original Investigation

Treatment of corticosteroid-resistant Graves’ orbitopathy with tocilizumab: a single-centre prospective study

Oliver Dorado Corteza Ophthalmology Department, Saint-Etienne University Hospital, Saint-Etienne, France;b Corneal Graft Biology, Engineering and Imaging Laboratory, EA2521, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, FranceCorrespondence[email protected]
View further author information
,
Damien Griveta Ophthalmology Department, Saint-Etienne University Hospital, Saint-Etienne, FranceView further author information
,
Nicolas Perrillata Ophthalmology Department, Saint-Etienne University Hospital, Saint-Etienne, FranceView further author information
,
Philippe Gaina Ophthalmology Department, Saint-Etienne University Hospital, Saint-Etienne, France;b Corneal Graft Biology, Engineering and Imaging Laboratory, EA2521, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, FranceView further author information
&
Gilles Thureta Ophthalmology Department, Saint-Etienne University Hospital, Saint-Etienne, France;b Corneal Graft Biology, Engineering and Imaging Laboratory, EA2521, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France;c Institut Universitaire de France, Paris, FranceView further author information
Pages 411-417 | Received 28 Jan 2022, Accepted 25 Aug 2022, Published online: 05 Sep 2022

References

  • Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18(9):959–965. doi:10.1089/thy.2007.0407.
  • Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–738. doi:10.1056/NEJMra0905750.
  • Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med. 2009;360(10):994–1001. doi:10.1056/NEJMcp0806317.
  • Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, et al. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18(9):983–988. doi:10.1089/thy.2007.0404.
  • Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273–285. doi:10.1530/EJE-07-0666.
  • Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5(1):9–26. doi:10.1159/000443828.
  • Zang S, Ponto KA, Pitz S, Kahaly GJ. Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy. J Endocrinol Invest. 2011;34(11):876–880. doi:10.1007/BF03346732.
  • Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–332. doi:10.1210/jc.2010-1962.
  • Molnár I, Balázs C. High circulating IL-6 level in Graves’ ophthalmopathy. Autoimmunity. 1997;25(2):91–96. doi:10.3109/08916939708996275.
  • Murakami M, Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr Opin Rheumatol. 2011;23(3):273–277. doi:10.1097/BOR.0b013e3283456797.
  • Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann N Y Acad Sci. 2009;1182:111–123. doi:10.1111/j.1749-6632.2009.05159.x.
  • Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162–167. doi:10.1097/IOP.0000000000000037.
  • Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodríguez Alvarez FM, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–190. doi:10.1016/j.ajo.2018.07.038.
  • Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47(1):9–14. [published correction appears in Clin Endocrinol (Oxf) 1997 Nov;47(5):632. doi:10.1046/j.1365-2265.1997.2331047.x.
  • Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639–644. doi:10.1136/bjo.73.8.639.
  • European Group on Graves’ Orbitopathy (EUGOGO), Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155(3):387–389. doi:10.1530/eje.1.02230.
  • Sy A, Eliasieh K, Silkiss RZ. Clinical response to tocilizumab in severe thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2017;33(3):e55–e57. doi:10.1097/IOP.0000000000000730.
  • Pascual-Camps I, Molina-Pallete R, Bort-Martí MA, Todolí J, España-Gregori E. Tocilizumab as first treatment option in optic neuropathy secondary to Graves’ orbitopathy. Orbit. 2018;37(6):450–453. doi:10.1080/01676830.2018.1435694.
  • Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234–5240. doi:10.1210/jc.2005-0148.
  • Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454–4463. doi:10.1210/jc.2012-2389.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.